کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2120879 | 1546896 | 2016 | 11 صفحه PDF | دانلود رایگان |
• We identified 7398 awards for infectious disease research awarded to UK institutions across 1997–2013, with total funding of £3.7 billion.
• We compared research investment with global burden of disease. Acute hepatitis C, trypanosomiasis and leishmaniasis appear relatively well funded shigellosis, pertussis, cholera and syphilis consistently rank lowest for research funding relative to their disease burden.
• Tuberculosis typically ranked lower than HIV or malaria, and pneumonia receives low levels of investment when considering global burdens.
• By demonstrating potential inequities in allocation of investment, results can help to inform policymakers, funding agencies and researchers.
BackgroundInfectious diseases account for a significant global burden of disease and substantial investment in research and development. This paper presents a systematic assessment of research investments awarded to UK institutions and global health metrics assessing disease burden.MethodsWe systematically sourced research funding data awarded from public and philanthropic organisations between 1997 and 2013. We screened awards for relevance to infection and categorised data by type of science, disease area and specific pathogen. Investments were compared with mortality, disability-adjusted life years (DALYs) and years lived with disability (YLD) across three time points.FindingsBetween 1997–2013, there were 7398 awards with a total investment of £3.7 billion. An increase in research funding across 2011–2013 was observed for most disease areas, with notable exceptions being sexually transmitted infections and sepsis research where funding decreased. Most funding remains for pre-clinical research (£2.2 billion, 59.4%). Relative to global mortality, DALYs and YLDs, acute hepatitis C, leishmaniasis and African trypanosomiasis received comparatively high levels of funding. Pneumonia, shigellosis, pertussis, cholera and syphilis were poorly funded across all health metrics. Tuberculosis (TB) consistently attracts relatively less funding than HIV and malaria.InterpretationMost infections have received increases in research investment, alongside decreases in global burden of disease in 2013. The UK demonstrates research strengths in some neglected tropical diseases such as African trypanosomiasis and leishmaniasis, but syphilis, cholera, shigellosis and pneumonia remain poorly funded relative to their global burden. Acute hepatitis C appears well funded but the figures do not adequately take into account projected future chronic burdens for this condition. These findings can help to inform global policymakers on resource allocation for research investment.
Journal: EBioMedicine - Volume 3, January 2016, Pages 180–190